Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!
Valeant Said to Be in Talks to Acquir...
Home  »  Community News  »  Valeant Said to Be i...
Valeant Said to Be in Talks to Acquire Egyptian Drugmaker Amoun – Courtesy (Fierce Pharma)
Pharma News

Valeant’s ($VRX) next pickup could come from the Middle East, where it’s reportedly in deal talks with one of Egypt’s largest drugmakers, Amoun. That company could fetch between $700 million and $800 million, Bloomberg‘s sources say, though the talks are still in the early stages. Amoun would be Valeant’s third conquest since losing out on longtime target Allergan, following acquisitions ofSalix and the assets of bankrupt biotech Dendreon. If a transaction between the pair doesn’t go through, though, Amoun could go the IPO route,

Valeant Pharmaceuticals International Inc. is in talks to acquire one of the largest drugmakers in Egypt to expand in both veterinary and human medicines, according to people with knowledge of the matter.

Negotiations to buy Amoun Pharmaceutical Co. are at an early stage and may still fall apart, the people said, asking not to be identified because the discussions are private. Should the company fail to find a buyer, it may instead consider an initial public offering in London, two of the people said.

A sale of Amoun, which could value the company at $700 million to $800 million, according to one of the people, would be one of the largest acquisitions of a pharmaceutical company in the Middle East, signaling a growing desire among international companies to expand in the region’s fast-growing economies. Kellogg Co. agreed to acquire confectioner Bisco Misr in January, beating out competition from buyout firm Abraaj Group of the United Arab Emirates.

Amoun’s owners hired Goldman Sachs Group Inc. as an adviser, Bloomberg News reported in March. Shareholders are working with Goldman Sachs to pursue options including a sale, Chief Executive Officer Mohamed Roushdy said by phone at the time.

The company’s shareholders include emerging market-focused private-equity arms of Capital Group, Concord International Investments, and the Rohatyn Group, the New York-based fund that agreed to acquire Citigroup Inc.’s buyout business in 2013. The investors bought Amoun for about $450 million in 2006.

Valeant, based in Laval, Quebec, is seeking to become one of the world’s biggest drug companies, mainly through a series of acquisitions, as the pharmaceutical industry rushes to consolidate.

Last year it lost out to Actavis Plc. in an attempt to acquire Botox-maker Allergan Inc., through a joint venture with Bill Ackman’s Pershing Square Capital Management LP. In March, Valeant beat Endo International Plc in a bidding war to acquire Salix Pharmaceuticals Inc. for $11.1 billion.

Representatives for Amoun, Rohatyn and Valeant declined to comment, while representatives for Capital Group and Concord International didn’t respond to requests for comment.

Leave a reply

You must be logged in to post a comment.